Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis

Abstract

Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.

What is claimed is: 
     
         1 - 133 . (canceled) 
     
     
         134 . A method of treating cancer in a subject comprising administering to the subject an effective amount of a strain of  Bifidobacterium animalis  ssp.  lactis  comprising a genome having at least 95% sequence identity to the genome of  Bifidobacterium animalis  ssp.  lactis  Strain A (ATCC Deposit Number PTA-125097) to treat the cancer. 
     
     
         135 . The method of  claim 134 , wherein the cancer is a non-small cell lung cancer, a colorectal cancer, a triple negative breast cancer, a bladder cancer, a gastroesophageal cancer, a renal cell carcinoma, or a solid tumor. 
     
     
         136 . The method of  claim 134 , wherein the bacterial composition is administered orally. 
     
     
         137 . The method of  claim 134 , wherein the bacterial composition is formulated as a capsule or a tablet. 
     
     
         138 . The method of  claim 134 , wherein the bacterial composition comprises at least 7.5×10 10  colony forming units (CFUs) of  Bifidobacterium animalis  ssp.  lactis.    
     
     
         139 . The method of  claim 134 , wherein the bacterial composition is administered at least once daily. 
     
     
         140 . The method of  claim 134 , wherein the bacterial composition is administered twice daily. 
     
     
         141 . The method of  claim 134 , wherein the bacterial composition is administered in two or more doses. 
     
     
         142 . The method of  claim 134 , wherein the method further comprises administering to the subject a second cancer therapy. 
     
     
         143 . The method of  claim 142 , wherein the second cancer therapy is administered once every 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. 
     
     
         144 . The method of  claim 142 , wherein the second cancer therapy comprises cancer immunotherapy. 
     
     
         145 . The method of  claim 144 , wherein the cancer immunotherapy comprises administering an immune checkpoint inhibitor to the subject. 
     
     
         146 . The method of  claim 145 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. 
     
     
         147 . The method of  claim 146 , wherein the anti-PD-1 antibody is nivolumab or pembrolizumab. 
     
     
         148 . The method of  claim 147 , wherein pembrolizumab is administered intravenously. 
     
     
         149 . The method of  claim 145 , wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody. 
     
     
         150 . The method of  claim 149 , wherein the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab. 
     
     
         151 . The method of  claim 149 , wherein the anti-PD-L1 antibody is administered intravenously. 
     
     
         152 . The method of  claim 145 , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody. 
     
     
         153 . The method of  claim 152 , wherein the anti-CTLA-4 antibody is ipilimumab. 
     
     
         154 . The method of  claim 153 , wherein ipilimumab is administered intravenously. 
     
     
         155 . A pharmaceutical composition formulated for oral administration comprising a strain of  Bifidobacterium animalis  ssp.  Lactis  comprising a genome having at least 95% sequence identity to the genome of  Bifidobacterium animalis  ssp.  lactis  Strain A (ATCC Deposit Number PTA-125097) and a pharmaceutically acceptable carrier with an enteric coating. 
     
     
         156 . The pharmaceutical composition of  claim 155 , wherein the pharmaceutical composition is formulated in an enteric coated capsule. 
     
     
         157 . The pharmaceutical composition of  claim 155 , wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2. 
     
     
         158 . The pharmaceutical composition of  claim 155 , wherein the pharmaceutical composition comprises an enteric coated tablet. 
     
     
         159 . The pharmaceutical composition of  claim 155 , wherein the  Bifidobacterium animalis  ssp.  Lactis  Strain are live bacteria or freeze-dried.